VJHemOnc is committed to improving our service to you

EHA 2015 | Emerging anti-CD20 monoclonal antibodies as first-line therapy in elderly CLL

VJHemOnc is committed to improving our service to you

Paolo Ghia

At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the results of clinical trials of anti-CD20 monoclonal antibodies in combination with chloramubucil, obinutuzumab plus chloramubucil and ofatumumab plus chlorambucil, for first-line therapy in older patients with chronic lymphocytic leukemia (CLL).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter